07 Sep Algon® by Lavipharm supports the event “WOMEN & Duchenne Muscular Dystrophy” hosted by MDA Hellas
Peania, 7 September 2022 – Lavipharm’s Greek analgesic product Algon® is sponsoring the online event “WOMEN & Duchenne Muscular Dystrophy”, which is being held today at 17:00 by MDA HELLAS, the Association for the Care of People with Neuromuscular Diseases. The event is being staged as part of World Duchenne Awareness Day (WDAD), observed every year on 7 September.
This year’s WDAD topic is “Women and Duchenne”, with the aim of informing and raising awareness among the public and the medical community of how Duchenne Muscular Dystrophy affects women. At today’s MDA Hellas event, doctors, healthcare professionals, scientific partners and members of MDA Hellas will share their expertise and experience in the management of the disease and the care of those afflicted with muscular dystrophy. The event will focus on the needs and challenges that women face in managing the disease.
Lavipharm is once again supporting events hosted by MDA Hellas to inform and raise awareness on Duchenne Muscular Dystrophy, with the Greek analgesic Algon®. Thanks to its pain-relieving, antipyretic and anti-inflammatory effect, Algon® is a reliable choice for the immediate treatment of headache and migraine.
You can watch the talk at the following link: https://www.livemedia.gr/mdahellasduchenne22
